Ionis CEO exercises options and sells shares
Ionis Pharmaceuticals Chief Executive Officer Brett P. Monia reported an exercise-and-sell transaction in company stock.
Rhea-AI Filing Summary
Ionis Pharmaceuticals Chief Executive Officer Brett P. Monia reported an exercise-and-sell transaction in company stock. On May 13–14, Monia exercised options to acquire a total of 4,536 shares of common stock at an exercise price of $32.60 per share, then sold the same number of shares in open-market trades at weighted average prices of about $78.01 and $78.68. The sales were carried out under a pre-arranged Rule 10b5-1 Trading Plan adopted on December 8, 2025. Following these transactions, Monia directly holds 242,662 shares of Ionis common stock, indicating that only a small portion of the position was sold.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 4,536 shares ($208K approx. pre-tax spread)
Exercise and Sale
6 txns
Insider
Monia Brett P
Role
Chief Executive Officer
Sold
4,536 shs ($356K)
Approx. gross sale proceeds
$356K
Approx. exercise cost
$148K
Approx. pre-tax spread
$208K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (right to buy) | 3,220 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,220 | $32.60 | $105K |
| Sale | Common Stock | 3,220 | $78.6793 | $253K |
| Exercise | Non-Qualified Stock Option (right to buy) | 1,316 | $0.00 | $0.00 |
| Exercise | Common Stock | 1,316 | $32.60 | $43K |
| Sale | Common Stock | 1,316 | $78.013 | $103K |
Holdings After Transaction:
Non-Qualified Stock Option (right to buy) — 35,637 contracts (Direct);
Common Stock — 242,662 shares (Direct)
Footnotes (3)
- F1. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 8, 2025
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.00 to $78.025 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
- F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.075 to $79.01 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
Key Figures
Shares sold: 4,536 shares
Sale price May 13: $78.0130 per share
Sale price May 14: $78.6793 per share
+3 more
6 metrics
Shares sold
4,536 shares
Total open-market sales on May 13–14, 2026
Sale price May 13
$78.0130 per share
Weighted average price for 1,316 shares sold
Sale price May 14
$78.6793 per share
Weighted average price for 3,220 shares sold
Options exercised
4,536 shares
Non-qualified stock options converted to common stock
Exercise price
$32.60 per share
Conversion price for exercised non-qualified stock options
Shares held after
242,662 shares
Direct common stock ownership following transactions
Key Terms
Rule 10b5-1 Trading Plan, Non-Qualified Stock Option, weighted average price
3 terms
Rule 10b5-1 Trading Plan regulatory
"Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Non-Qualified Stock Option financial
"Non-Qualified Stock Option (right to buy) with a conversion or exercise price of $32.6000"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
weighted average price financial
"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
FAQ
What insider transaction did Ionis (IONS) CEO Brett Monia report?
Ionis CEO Brett Monia reported exercising stock options and selling the resulting shares. He exercised 4,536 options at $32.60 per share and sold the same number of common shares in open-market transactions on May 13–14, 2026, under a Rule 10b5-1 plan.
Were the recent Ionis (IONS) CEO stock sales pre-planned?
Yes. The reported stock sales were executed pursuant to a Rule 10b5-1 Trading Plan. The plan was adopted by Brett Monia on December 8, 2025, indicating the trades were pre-scheduled rather than timed discretionarily around short-term market or company developments.
What stock options did the Ionis (IONS) CEO exercise in this Form 4?
Brett Monia exercised non-qualified stock options covering 4,536 shares of Ionis common stock. These options had a conversion or exercise price of $32.60 per share and were originally exercisable beginning January 3, 2023, with an expiration date of January 2, 2032.
AI-generated analysis. How Rhea-AI works. Not financial advice.
